Elly Barry is a board-certified pediatrician and pediatric hematologist/oncologist with over 15 years of experience in drug development, currently serving as the Senior Vice President and Head of Clinical Development at Day One Biopharmaceuticals, a company focused on developing medicines for childhood and adult cancers and other rare diseases. Prior to Day One, Elly worked for 7-years at Pfizer as the Global Clinical Lead for Pediatric Oncology and head of the Pfizer’s Pediatric Oncology Leadership Team, overseeing pediatric oncology clinical development and responsible for developing and implementing strategy and deliverables related to pediatric oncology development plans.
Elly received her MD degree from Yale University School of Medicine in New Haven, before completing residency training in pediatrics at Tufts-New England Medical Center/Floating Hospital for Children in Boston, and fellowship training in pediatric hematology/oncology at Boston Children’s Hospital/Dana-Farber Cancer Institute in Boston. She remained on staff at DFCI as an Instructor in Pediatric Hematology/Oncology and Bone Marrow Transplantation, while obtaining a Masters in Medical Science degree from Harvard Medical School. Her previous industry roles at Genzyme and Millennium have focused on the early and late development of drugs for hematologic malignancies, breast, and renal cancers.
Elly also serves on the Industry Advisory Council for CureSearch (https://curesearch.org/) , is a member of the ACCELERATE Platform Steering Committee (https://www.accelerate-platform.org/), and served as the Co-Chair the Pediatrics Specialty Committee of BIO (https://www.bio.org/) from 2020-2022.